# US 7,790,465 B2 · Methods, systems and computer programs for assessing CHD risk using adjusted LDL particle number measurements

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,790,465 B2
- Document ID: US7790465B2
- Status: Granted
- Kind: B2
- Application number: 11/379,275
- Filed: 2006-04-19
- Published: 2006-08-17
- Granted: 2010-09-07
- Earliest claimed: 2003-10-23
- Assignees: LipoScience, Inc.
- Inventors: James D. Otvos
- Web page: https://patentgrep.com/patent/US7790465B2

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 2800/32: Cardiovascular disorders
- Y10T 436/24: Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Methods, computer program products and apparatus determine a subject's risk of having or developing CHD using a calculated LDL particle risk number and/or a mathematical model of risk associated with LDL particles that adjusts concentrations of at least one of small and large LDL particle measurements to reflect predicted CHD risk.

## Claims

### Claim 1

A method of determining a subject's risk of having and/or developing coronary heart disease (“CHD”), comprising:
obtaining concentration measurements of both small and large Low Density Lipoprotein (LDL) subclass particles in a blood plasma or serum sample of a subject; and
programmatically adjusting at least one of the small and large LDL subclass particle measurements to increase or decrease at least one of the measurements; and
determining the subject's risk of having and/or developing CHD based on both the small and large LDL subclass particle measurements, wherein at least one of the small and large LDL subclass measurements is the at least one adjusted LDL subclass particle measurement.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the measured large LDL subclass measurement is programmatically increased relative to the measured small LDL subclass measurement, the method further comprising electronically combining the increased large LDL subclass particle measurement and the small LDL subclass particle measurement to electronically automatically generate an LDL risk factor value, and wherein the determining step is based on the LDL risk factor value.

### Claim 3 (depends on 2)

A method according to claim 2, wherein the obtaining step comprises obtaining the concentration of Intermediate Density Lipoprotein (IDL) particles, and wherein the adjusting step is carried out so that the IDL particle measurement and the large LDL subclass particle measurement are increased relative to the small LDL subclass particle measurement.

### Claim 4 (depends on 1)

A method according to claim 1, wherein the adjusting step mathematically increases the measurement of the large LDL subclass particle measurement in units of concentration.

### Claim 5 (depends on 4)

A method according to claim 4, wherein the adjusting step is based on a predetermined mathematical model that predicts a subject's cardiovascular risk, and wherein the mathematical model comprises a first weighting factor for the obtained concentration measurement of small LDL subclass particles and a second different weighting factor for the obtained concentration measurement of large LDL subclass particles.

### Claim 6 (depends on 5)

A method according to claim 5, wherein the first and second weighting factors are multiplied to the respective small and large LDL subclass particle measurements and the results are added together to provide a weighted LDL particle risk factor number.

### Claim 7 (depends on 1)

A method according to claim 1, wherein the adjusting step is carried out so that the large LDL subclass particle measurement is increased relative to the small LDL particle subclass concentration.

### Claim 8 (depends on 1)

A method according to claim 1, wherein the obtaining step comprises substantially concurrently obtaining NMR derived concentration measurements of small and large LDL subclass particles.

### Claim 9

A method of determining a subject's risk of having and/or developing CHD (coronary heart disease), comprising:
measuring concentrations of small and large LDL (Low Density Lipoprotein) subclass particles in an in vitro blood plasma and/or serum sample of a subject; and
programmatically adjusting at least one of the small or large LDL subclass particle concentration measurements by increasing or decreasing the at least one measurement based on a predetermined mathematical model, and determining the subject's LDL-based risk of CHD based on both the small and large LDL subclass particle measurements, wherein at least one of the small and large LDL subclass measurements is the at least one adjusted LDL subclass particle measurement.

### Claim 10 (depends on 9)

A method according to claim 9, further comprising measuring concentration of Intermediate Density Lipoprotein (IDL) particles in the sample, and wherein the adjusting step is carried out to electronically adjust at least two of the small LDL subclass measurement, the large LDL subclass particle measurement and the IDL particle measurement and calculating an LDL risk number based on the adjusted particle measurements.

### Claim 11

A method for determining a subject's risk of CHD coronary heart disease), comprising:
obtaining NMR derived concentration measurements of small and large LDL (low density lipoprotein) subclass particles in a biosample of the subject;
applying a weighting factor to at least one of the measured large and small LDL particle concentrations to increase or decrease one of the measured particle concentrations relative to the other; and
calculating a LDL risk predictor number for the subject using both the small and large LDL particle concentrations, wherein at least one of the small and large LDL particle concentrations is the weighted LDL particle concentration(s).

### Claim 12 (depends on 11)

A method according to claim 11, wherein the applying step comprises applying a weighting factor to the large LDL particle concentration, wherein the calculating step uses the weighted large LDL particle concentration summed with the small LDL particle concentration to generate the LDL risk predictor number for the subject.

### Claim 13 (depends on 12)

A method according to claim 12, wherein the obtaining step comprises deconvolving at least one NMR spectroscopic signal of the biosample to calculate the small and large LDL particle subclass concentration measurements.

### Claim 14 (depends on 13)

A method according to claim 13, wherein the obtaining step obtains a concentration measure of intermediate density lipoprotein (IDL) particles, and wherein the applying step is carried out to increase the IDL particle measurement and the large LDL particle measurement relative to the small LDL to obtain weighted large LDL and IDL particle measurements, subclass particle measurement and the calculating step uses the weighted large LDL and IDL particle measurements to generate the LDL risk predictor number.

### Claim 15 (depends on 14)

A method according to claim 14, wherein the biosample is an in vitro blood plasma and/or serum sample, and wherein the applying step is carried out to increase the IDL particle measurement greater than the large LDL particle measurement and the calculating step uses the weighted large LDL and IDL particle measurements to generate the LDL risk predictor number.

### Claim 16 (depends on 11)

A method according to claim 11, wherein the applying step is carried out to apply a first weight to the large LDL subclass concentration and a second weight relative to the small LDL subclass concentration with the first weight being greater than the second weight to calculate the LDL risk predictor number.

### Claim 17

A computer program product for adjusting measured in vitro concentrations of LDL (low density lipoprotein) particles to assess CHD (coronary heart disease) risk, the computer program product comprising:
a computer readable storage medium having computer readable program code embodied in said medium, said computer-readable program code comprising:
computer readable program code that adjusts measured in vitro concentrations of at least one of small and large LDL (low density lipoprotein) particle subclasses to increase or decrease at least one of the small and large LDL particle subclass concentrations; and
computer readable program code that generates a LDL risk number using both the small and large LDL subclass particle concentrations and the adjusted concentration of at least one of the small and large LDL particle subclass concentrations to reflect a subject's risk of having or developing CHD.

### Claim 18 (depends on 17)

A computer program product according to claim 17, further comprising computer readable program code that deconvolutes at least one NMR signal of a patient biosample into measured concentrations of small and large LDL particle subclasses.

### Claim 19 (depends on 17)

A computer program product according to claim 17, wherein the computer readable program code that adjusts the measured concentrations is configured to increase the measured large LDL particle concentration relative to the small LDL particle concentration, and wherein the computer readable code that generates the LDL risk number uses the increased large LDL particle concentration to define the LDL risk number.

### Claim 20 (depends on 17)

A computer program product according to claim 17, wherein the computer readable program code that adjusts at least one of the measured small and large LDL particle concentrations is configured to adjust at least two of small LDL particle concentration, large LDL particle concentration and intermediate density lipoprotein (IDL) particle concentration such that both the large LDL and IDL particle concentrations are increased relative to the small LDL subclass concentration, and wherein the computer readable code that generates the LDL risk number uses the at least two adjusted particle concentrations to generate the LDL risk number.

### Claim 21 (depends on 17)

A computer program product according to claim 17, wherein the computer readable program code that generates the LDL risk number is configured to add the adjusted small and/or large LDL particle concentrations and scale the summation to thereby define a corresponding scalar LDL-based CHD risk.

### Claim 22 (depends on 17)

A computer program product according to claim 17, wherein the computer readable program code that generates the LDL risk number combines the small and large LDL particle measurements, at least one of which being adjusted, and calculates a single LDL particle risk number in units of concentration.

### Claim 23 (depends on 17)

A computer program product according to claim 17, wherein the computer readable program code that adjusts measured in vitro concentrations is configured to apply different weighting factors for small and large LDL particle concentrations, and wherein the computer readable code that generates the LDL risk number uses the weighted small and large LDL particle concentrations to predict CHD risk.

### Claim 24 (depends on 17)

A computer program product according to claim 17, wherein the computer readable program code that adjusts measured in vitro concentrations is configured to increase the large LDL particle measurement relative to the small LDL particle measurement.

### Claim 25 (depends on 17)

A computer program product according to claim 17, wherein the computer readable program code that adjusts the LDL particle concentrations is configured to multiply a first weighting factor for the concentration measurement of small LDL particles and multiply a second different weighting factor for the concentration measurement of large LDL particles, and wherein the computer readable program code that generates the LDL risk number sums the weighted small and large LDL particle concentrations.

### Claim 26 (depends on 25)

A computer program product according to claim 25, wherein the computer readable program code that generates the LDL risk number is configured to scale the sum of the multiplied small and large LDL particle concentration measurements to provide a scalar weighted LDL particle risk number.

### Claim 27 (depends on 26)

A computer program product according to claim 26, wherein the computer readable program code that generates the LDL risk number is configured to increase the large LDL particle concentration measurement relative to the small LDL particle concentration measurement.

### Claim 28

An apparatus for obtaining data regarding lipoprotein constituents in a subject, comprising:
an NMR spectrometer for acquiring at least one NMR spectrum of an in vitro blood plasma or serum sample of a subject; and
at least one processor in communication with the NMR spectrometer, the at least one processor configured to (a) determine concentrations of small and large LDL (low density lipoprotein) particle subclasses in the sample from the subject, (b)
increase or decrease at least one of the determined small and large LDL particle concentrations to provide at least one adjusted concentration value, and (c) determine the subect's risk of developing or having CHD (coronary heart disease) based on both the small and large LDL subclass measurements, wherein at least one of the small and large LDL subclass measurements is the at least one adjusted concentration value.

### Claim 29 (depends on 28)

An apparatus according to claim 28, wherein the at least one NMR spectrum is a composite spectrum, the at least one processor further configured to define a plurality of individual NMR constituent spectra, each associated with a selected reference lipoprotein constituent signal lineshape, each constituent spectrum having associated spectra that contribute to the composite NMR spectrum of the blood plasma or serum sample.

### Claim 30 (depends on 28)

An apparatus according to claim 28, wherein the processor is configured to increase the measured large LDL particle concentration using a defined multiplier relative to the small LDL particle concentration to generate the adjusted concentration value.

### Claim 31 (depends on 30)

An apparatus according to claim 30, wherein the processor is configured to generate an LDL risk number using adjusted small and large LDL particle concentrations, wherein the processor is configured to multiply a first weighting factor to the small LDL particle concentration and a second different weighting factor to the large LDL particle concentration, and wherein the second weighting factor is larger than the first weighting factor.

### Claim 32 (depends on 28)

An apparatus according to claim 28, wherein the at least one processor is configured to determine a concentration of IDL (intermediate density lipoprotein) particles in the sample and increase the IDL concentration as well as the concentration of large LDL particles relative to the small LDL particle concentration and wherein the at least one processor is configured to determine the subect's CHD risk using the increased IDL and large LDL particle concentrations.

### Claim 33 (depends on 32)

An apparatus according to claim 32, wherein the at least one processor is configured to determine an LDL risk number using the increased LDL and IDL particle concentrations to determine the subject's CHD risk.

### Claim 34

A method of calculating an LDL risk parameter number used to assess a person's risk of having or developing CHD (coronary heart disease) comprising:
calculating a LDL risk parameter number for a person by adding together adjusted concentrations of at least two of small low density lipoprotein (LDL), large LDL and IDL (intermediate density lipoprotein) particle measured concentrations whereby the adjusted concentrations are increased or decreased relative to the measured particle concentrations, wherein at least one of the adjusted large LDL or IDL particle concentrations is increased relative to the measured small LDL particle concentration, wherein the LDL risk parameter number defines the person's risk of having or developing CHD, and wherein increased risk is associated with greater values of the LDL risk parameter number.

### Claim 35 (depends on 34)

A method according to claim 34, further comprising electronically defining a risk of developing or having CHD associated with the LDL risk parameter number.

### Claim 36 (depends on 34)

A method according to claim 34, further comprising mathematically scaling the calculated LDL risk parameter number to thereby provide a scalar risk number that defines the CHD risk.

### Claim 37 (depends on 34)

A method according to claim 34, wherein both the measured IDL and large LDL particle concentrations are increased relative to the measured small LDL particle concentration to provide the adjusted concentrations and, wherein the adjusted IDL and LDL particle concentrations are added to the small LDL particle concentration to generate the LDL risk parameter number.

### Claim 38 (depends on 37)

A method according to claim 37, wherein the IDL particle concentration is increased more than the large LDL particle concentration to provide the adjusted concentrations.
